Table 1 Clinical and biological characteristics of COVID-19 patients
|  | All patients (n = 20) | ||
|---|---|---|---|
Demographics | |||
 Gender, male (%) | 14 (70.0) | ||
 Age | 71 [66, 72] | ||
 Body mass index | 32 [28–36] | ||
Comorbidities | |||
 Comorbidity (%) | 9 (50.0) | ||
 Immunosuppressive therapy (%) | 1 (5.6) | ||
 Diabetes (%) | 4 (23.5) | ||
Delay from symptom onset, days | 9.0 [7.0, 11.0] | ||
Severity scores at admission | |||
 SOFA | 5.0 [4.0, 7.0] | ||
 SAPS II | 37.0 [30.3, 44.3] | ||
 PaO2/FiO2 | 116.0 [68.3, 151.5] | ||
Organ failures during ICU stay | |||
 Invasive mechanical ventilation (%) | 18 (90) | ||
 Vasoactive drugs (%) | 15 (83.3) | ||
 Renal replacement therapy (%) | 4 (22.2) | ||
Follow-up | Â | ||
 Concurrent bacterial infection at D0 (%) | 9 (45) | ||
 ICU-acquired infection before D20 (%) | 15 (75) | ||
 SOFA score at D20 | 6.5 [5.00, 8.00] | ||
 Corticotherapy in ICU (%) | 18 (90) | ||
 Mechanical ventilation duration | 21.5 [16.5, 32.5] | ||
 Days in ICU | 28.0 [24.3, 39.5] | ||
 Days in Hospital | 32.5 [25.8, 45.8] | ||
 Day-28 mortality | 7 (35) | ||
 Day-90 mortality | 9 (45) | ||
Status at time of sampling | D0 | D20 | |
 Invasive mechanical ventilation | 8 (40) | 14 (70) | |
 Hospitalized in ICU | 20 (100) | 20 (100) | |
Laboratory values | D0 (n = 19) | D20 (n = 18) | p-value |
 Lymphocyte (cells/µL) | 534 [392, 751] | 1 055 [713, 1 488] | 0.003 |
 CD3 + lymphocytes (cells/µL) | 355 [214, 445] | 760 [422, 967] | 0.001 |
 CD4 + lymphocytes (cells/µL) | 189 [117, 316] | 415 [228, 590] | 0.003 |
 CD8 + lymphocytes (cells/µL) | 103 [82, 198] | 262 [114, 430] | 0.018 |
 mHLA-DR expression (Ab/C) | 6 548 [4 622, 11 704] | 6 855 [5 946, 13 897] | 0.741 |